Distribution into the training (+), invisible training (-), calibration (#), and validation (*) sets is done via the first symbol in each line of the input file. Table S1 contains the first split for gamma secretase inhibitors. Table S2 contains the first split for substances with blood brain barrier permeation (logBB).
. The ID and SMILES used to represent 233 gamma-secretase inhibitors which are potential agents for treatment Alzheimer's disease together with their binding affinity.
-CHEMBL370107 OC1CCC(CC1)(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1 6.700 +CHEMBL370729 Fc1ccc(F)c(c1)C1(CC2CCC(C2)C1)S(=O)(=O)c1ccc(Cl)cc1 7.280 -CHEMBL191195 Clc1ccc(cc1)S(=O)(=O)C1(CCCCC1)c1ccccc1 6.340 +CHEMBL191246 Fc1ccccc1C1(CCCCC1)S(=O)(=O)c1ccc(Cl)cc1 7.260 -CHEMBL191301 CC(C)N(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1 6.770 #CHEMBL191302 C[C@H](CO)N(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1 7.570 #CHEMBL191887 CC(C)C(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1 7.150 #CHEMBL192356 CC(CCO)C(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1 7.460 +CHEMBL192393 COC(=O)C(C)C(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1
6.600 -CHEMBL193111 CC(CO)C(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1
6.520 -CHEMBL194820 Fc1ccc(F)c(CS(=O)(=O)c2ccc(Cl)cc2)c1 5.360 #CHEMBL195105 CC(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1 5.610 #CHEMBL195200 Fc1cccc(c1)C1(CCCCC1)S(=O)(=O)c1ccc(Cl)cc1 6.600 +CHEMBL363802 Fc1ccc(F)c(c1)C1(CCCCC1)S(=O)(=O)c1ccccc1 7.010 *CHEMBL364042 CN(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1 5.720 #CHEMBL366006 COC(=O)C1CC(CCC1=O)(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1 6.980 *CHEMBL366022 Fc1ccc(F)c(c1)C1(CCC(=O)CC1)S(=O)(=O)c1ccc(Cl)cc1
7.660 -CHEMBL425566 Fc1ccc(F)c(c1)C1(CCCCC1)S(=O)(=O)c1ccc(Cl)cc1 8.520 +CHEMBL209384 CC(N(c1ccccc1)S(=O)(=O)c1ccc(Br)cc1)c1ccccc1OCCCN1CCCC1 5.720 +CHEMBL209739 CC(N(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1)c1ccccc1OCCCN1CCCCC1 5.680 +CHEMBL211428 CC(N(c1ccccc1)S(=O)(=O)c1ccccc1)c1ccccc1OCCCN1CCCC1 6.160 +CHEMBL211955 CC(N(c1ccccc1C(=O)c1ccccc1)S(=O)(=O)c1ccc(Cl)cc1)c1ccccc1OCCCN1CCCC1 5.920 +CHEMBL212926 CC(N(c1ccc(cc1)C(=O)c1ccccc1)S(=O)(=O)c1ccc(Cl)cc1)c1ccccc1OCCCN1CCCC1
5.490 -CHEMBL213231 CC(N(c1ccccc1)S(=O)(=O)c1ccc(Cl)cc1)c1ccccc1OCCCN1CCCC1 8.000 #CHEMBL213557 CC (N(c1ccc(Cl) 
6.970 -CHEMBL183326 O=S(=O)(NC1C2CCC1Cc1ccccc1C2)c1ccccc1 6.720 #CHEMBL183777 Clc1ccc(s1)S(=O)(=O)NC1C2CCC1Cc1ccccc1C2 7.210 +CHEMBL179060 CN1CCN(C/C=C/c2ccc3CC4CCC(Cc3c2)C4NS(=O)(=O)c2ccc(Cl)s2)CC1 7.410 -CHEMBL179519 Clc1ccc(s1)S(=O)(=O)NC1C2CCC1Cc1cc(/C=C/Cn3ccnc3)ccc1C2 7.820 *CHEMBL179524 OC1CCN(CCOc2ccc3CC4CCC(Cc3c2)C4NS(=O)(=O)c2ccc(Cl)s2)C1
6.680 -CHEMBL179982 CC1CCCCN1CCOc1ccc2CC3CCC(Cc2c1)C3NS(=O)(=O)c1ccc(Cl)s1
6.640 +CHEMBL180062 Clc1ccc(s1)S(=O)(=O)NC1C2CCC1Cc1cc(/C=C/CN3CCN(CC3)c3ccccc3)ccc1C2 7.680 #CHEMBL180118 CC1CCCN1CCOc1ccc2CC3CCC(Cc2c1)C3NS(=O)(=O)c1ccc(Cl)s1
6.470
7.160
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1.000 *156 NCCCN1C(C=CC=C3)=C3CCC2=C1C=CC=C2
1.060 - 
